Taking this into account, Evercore ISI downgraded its Organon & Co [OGN] rating to an In-line from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in early September from “a Neutral” to “an Underweight”. Goldman also remained covering OGN and has decreased its forecast on November 03, 2023 with a “Neutral” recommendation from previously “Buy” rating. Barclays started covering the stock on September 21, 2023. It rated OGN as “an Overweight”.
Price Performance Review of OGN
On Monday, Organon & Co [NYSE:OGN] saw its stock fall -9.07% to $8.72. Over the last five days, the stock has lost -31.45%. Organon & Co shares have fallen nearly -41.55% since the year began. Nevertheless, the stocks have fallen -53.69% over the past one year. While a 52-week high of $23.10 was reached on 02/13/25, a 52-week low of $9.18 was recorded on 05/05/25. SMA at 50 days reached $13.56, while 200 days put it at $16.65.
Levels Of Support And Resistance For OGN Stock
The 24-hour chart illustrates a support level at 8.43, which if violated will result in even more drops to 8.14. On the upside, there is a resistance level at 9.21. A further resistance level may holdings at 9.70. The Relative Strength Index (RSI) on the 14-day chart is 29.44, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.98, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.05%. Stochastics %K at 5.68% indicates the stock is a buying.
The most recent change occurred on March 16, 2023 when Raymond James began covering the stock and recommended ‘”an Outperform”‘ rating along with a $33 price target.
